Patents by Inventor Katsuhiko Mikoshiba
Katsuhiko Mikoshiba has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200157210Abstract: Provided is technology for using a given antigen-binding peptide as an intrabody that is functionable in a cell. An intracellular-stabilizer peptide consisting of 10 to 39 amino acids, at least 45% of the 10 to 39 amino acids being acidic amino acids, is fused with the antigen-binding peptide so as to be intracellularly expressed as a fusion protein.Type: ApplicationFiled: June 26, 2018Publication date: May 21, 2020Inventors: Katsuhiko MIKOSHIBA, Hiroyuki KABAYAMA
-
Patent number: 9803206Abstract: A therapeutic agent for treating a Trypanosoma-associated disease; a method of preventing infection by Trypanosoma parasites, or killing Trypanosoma parasites; and use thereof, the therapeutic agent and the method each using a mechanism different from a mechanism used in conventional technology. The therapeutic agent of the present invention for treating a Trypanosoma-associated disease includes, as a medicinal component, an antisense oligonucleotide suppressing the expression of an inositol 1,4,5-trisphosphate receptor protein of Trypanosoma parasites.Type: GrantFiled: October 8, 2014Date of Patent: October 31, 2017Assignee: RIKENInventors: Katsuhiko Mikoshiba, Takeshi Nara, Muneaki Hashimoto
-
Publication number: 20160193291Abstract: The present invention includes a treating step of treating neuronal growth cone with a regulatory factor to regulate macropinocytosis caused by a repulsive axon guidance molecule. The present invention can provide a new neuronal axon elongation regulating method etc.Type: ApplicationFiled: March 18, 2016Publication date: July 7, 2016Inventors: Katsuhiko MIKOSHIBA, Hiroyuki KABAYAMA
-
Patent number: 9314501Abstract: The present invention includes a treating step of treating neuronal growth cone with a regulatory factor to regulate macropinocytosis caused by a repulsive axon guidance molecule. The present invention can provide a new neuronal axon elongation regulating method etc.Type: GrantFiled: April 24, 2013Date of Patent: April 19, 2016Assignee: RIKENInventors: Katsuhiko Mikoshiba, Hiroyuki Kabayama
-
Publication number: 20150099795Abstract: A therapeutic agent for treating a Trypanosoma-associated disease; a method of preventing infection by Trypanosoma parasites, or killing Trypanosoma parasites; and use thereof, the therapeutic agent and the method each using a mechanism different from a mechanism used in conventional technology. The therapeutic agent of the present invention for treating a Trypanosoma-associated disease includes, as a medicinal component, an antisense oligonucleotide suppressing the expression of an inositol 1,4,5-trisphosphate receptor protein of Trypanosoma parasites.Type: ApplicationFiled: October 8, 2014Publication date: April 9, 2015Inventors: Katsuhiko Mikoshiba, Takeshi Nara, Muneaki Hashimoto
-
Patent number: 8937091Abstract: The present invention relates to: a ketone compound having transglutaminase-inhibiting activity, which is represented by the following Formula 1, 2, or 3: wherein R1 is a substituted or unsubstituted aryl or heterocyclyl group, R2, R3, and R4 are hydrogen atoms, n is 2, X is halogen, R5 and R6 independently represent a hydrogen atom or a substituted or unsubstituted C1-C10 alkyl, aryl, or aralkyl group, wherein R5 and R6 are not hydrogen atoms at the same time, or R5 and R6 may be taken together to form a saturated or unsaturated and substituted or unsubstituted heterocyclyl group containing a nitrogen atom (N); an inhibitor of protein crosslinking comprising the compound; and a composition for preventing or treating a protein-crosslinking causative disease, which comprises the compound or the protein crosslinking inhibitor.Type: GrantFiled: May 19, 2010Date of Patent: January 20, 2015Assignee: Japan Science and Technology AgencyInventors: Katsuhiko Mikoshiba, Kozo Hamada, Akiko Terauchi, Shouichirou Ozaki, Jun-ichi Goto, Etsuko Ebisui, Akinobu Suzuki
-
Patent number: 8853424Abstract: The present invention provides a protein cross-linking inhibitor containing a compound represented by any of the following formulas (1)-(13), or a pharmaceutically acceptable salt thereof: R3—[—X—B(ZR1)—Y—B(ZR2)—W—]n—R4,??(1) R3—[—X—B(ZR1)—Y—]n—R4,??(2) R3—[—B(ZR1)—Y—B(ZR2)—W—]n—R4,??(3) R3—[—X—B(ZR1)—]n—R4,??(4) R3—[—B(ZR2)—W—]n—R4,??(5) R3—X—B(ZR1)-T[B(ZR2)—W—R4]2,??(6) R3—B(OH)2,??(7) R3—B(ZR1)—X—B(ZR2)—R4,??(8) R3—B(R1)—O—B(R2)—R4,??(9) R3—[—X—B(ZR1)—Y—B(ZR2)—]n—R4,??(10) R3—[—X—B(ZR1)—Y—B(ZR2)—W-Q-]n—R4,??(11) R3—[—P—X—B(ZR1)—Y—B(ZR2)—W—]n—R4,??(12) [R3—X—B(ZR1)—Y]2B(ZR2),??(13) wherein each symbol is as defined in the DESCRIPTION.Type: GrantFiled: August 11, 2009Date of Patent: October 7, 2014Assignee: Japan Science and Technology AgencyInventors: Katsuhiko Mikoshiba, Nobuyuki Nukina, Shoichiro Ozaki, Kouzo Hamada, Jun-Ichi Goto, Akinobu Suzuki, Etsuko Ebisui, Akiko Terauchi
-
Publication number: 20130323769Abstract: The present invention provides a fusion protein including sarco/endoplasmic reticulum calcium ATPase, a fluorescence donor for FRET, and a fluorescence acceptor, one of the fluorescence donor and the fluorescence acceptor being linked to the N-terminus side of the ATPase, the other of the fluorescence donor and the fluorescence acceptor being inserted between the above one of the fluorescence donor and the fluorescence acceptor and the ATPase or being inserted in an amino acid sequence of the ATPase, the amino acid sequence corresponding to (i) amino acids 1 through 6 in SERCA2a, (ii) amino acids 369 through 380 in the SERCA2a or (iii) amino acids 572 through 583 in the SERCA2a.Type: ApplicationFiled: January 13, 2012Publication date: December 5, 2013Applicants: JAPAN SCIENCE AND TECHNOLOGY AGENCY, RIKENInventors: Katsuhiko Mikoshiba, Toru Matsu-Ura, Kanayo Satoh
-
Publication number: 20130296230Abstract: A method of the present invention for treating malaria includes the step of administering, to a human or an animal, a therapeutically effective amount of drug for suppressing calcium ion exit from an intracellular organelle of the malaria parasite to an outside of the intracellular organelle and/or calcium ion entry from an outside of a cell of the malaria parasite into the cell.Type: ApplicationFiled: October 27, 2011Publication date: November 7, 2013Applicant: RIKENInventors: Katsuhiko Mikoshiba, Masahiro Enomoto, Shin-Ichiro Kawazu
-
Publication number: 20130288977Abstract: The present invention includes a treating step of treating neuronal growth cone with a regulatory factor to regulate macropinocytosis caused by a repulsive axon guidance molecule. The present invention can provide a new neuronal axon elongation regulating method etc.Type: ApplicationFiled: April 24, 2013Publication date: October 31, 2013Applicant: RIKENInventors: Katsuhiko MIKOSHIBA, Hiroyuki KABAYAMA
-
Publication number: 20120277423Abstract: The present invention relates to: a ketone compound having transglutaminase-inhibiting activity, which is represented by the following Formula 1, 2, or 3: wherein R1 is a substituted or unsubstituted aryl or heterocyclyl group, R2, R3, and R4 are hydrogen atoms, n is 2, X is halogen, R5 and R6 independently represent a hydrogen atom or a substituted or unsubstituted C1-C10 alkyl, aryl, or aralkyl group, wherein R5 and R6 are not hydrogen atoms at the same time, or R5 and R6 may be taken together to form a saturated or unsaturated and substituted or unsubstituted heterocyclyl group containing a nitrogen atom (N); an inhibitor of protein crosslinking comprising the compound; and a composition for preventing or treating a protein-crosslinking causative disease, which comprises the compound or the protein crosslinking inhibitor.Type: ApplicationFiled: May 19, 2010Publication date: November 1, 2012Inventors: Katsuhiko Mikoshiba, Kozo Hamada, Akiko Terauchi, Shouichirou Ozaki, Jun-ichi Goto, Etsuko Ebisui, Akinobu Suzuki
-
Patent number: 8252547Abstract: The present invention provides a composition comprising an IP3 receptor-binding protein (IRBIT), a nucleic acid that controls the expression and translation of IRBIT, or an antibody against IRBIT for controlling at least one intracellular biological function selected from the group consisting of (1) protein synthesis, (2) phosphatidylinositol metabolism, and (3) intracellular pH.Type: GrantFiled: March 20, 2007Date of Patent: August 28, 2012Assignee: Japan Science and Technology AgencyInventors: Katsuhiko Mikoshiba, Hideaki Ando, Akihiro Mizutani
-
Patent number: 8017809Abstract: A bisboron compound represented by the general formula (I): wherein B represents a boron atom, Y represents an oxygen or sulfur atom, R1 and R2 independently represent a monocyclic aromatic group, a polycyclic aromatic group, or a heterocyclic group containing at least one heteroatom selected from oxygen, nitrogen and sulfur atoms, R3 represents a hydrogen atom; —(CH2)m—NR4R5; —CO—(CH2)m—NR4R5; —COCH(NH2)R6; —CHR7R8; —CH2CH(NH2)—R9; quinolyl substituted with C1-C4 alkyl group; or C1-C4 alkyl substituted with pyridyl, piperidino or pyrrolidinyl group, and X represents a monocyclic aromatic group, a polycyclic aromatic group or a heterocyclic group, which may be the same as or different from R1 and R2, or a bifunctional group having a monocyclic aromatic group, polycyclic aromatic group or heterocyclic group bonded to each side of a group selected from the group consisting of a single bond, O, CH2, S, SO2, CH2OCH2, OCH2, OCH2CH2OCH2, OCH2OCH2CH2 and CH2OCH2CH2, or a salt thereof, and a composition for contrType: GrantFiled: November 24, 2006Date of Patent: September 13, 2011Assignee: Japan Science and Technology AgencyInventors: Katsuhiko Mikoshiba, Shoichiro Ozaki, Akinobu Suzuki, Takeshi Nakamura, Kyoko Nakamura, legal representative, Aiko Nakamura, legal representative
-
Publication number: 20110212919Abstract: The present invention provides a protein cross-linking inhibitor containing a compound represented by any of the following formulas (1)-(13), or a pharmaceutically acceptable salt thereof: R3—[—X—B(ZR1)—Y—B(ZR2)—W—]n—R4,??(1) R3—[—X—B(ZR1)—Y—]n—R4,??(2) R3—[—B(ZR1)—Y—B(ZR2)—W—]n—R4,??(3) R3—[—X—B(ZR1)—]n—R4,??(4) R3—[—B(ZR2)—W—]n—R4,??(5) R3—X—B(ZR1)-T[B(ZR2)—W—R4]2,??(6) R3—B(OH)2,??(7) R3—B(ZR1)—X—B(ZR2)—R4,??(8) R3—B(R1)—O—B(R2)—R4,??(9) R3—[—X—B(ZR1)—Y—B(ZR2)—]n—R4,??(10) R3—[—X—B(ZR1)—Y—B(ZR2)—W-Q-]n—R4,??(11) R3—[—P—X—B(ZR1)—Y—B(ZR2)—W—]n—R4,??(12) [R3—X—B(ZR1)—Y]2B(ZR2),??(13) wherein each symbol is as defined in the DESCRIPTION.Type: ApplicationFiled: August 11, 2009Publication date: September 1, 2011Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Katsuhiko Mikoshiba, Nobuyuki Nukina, Shoichiro Ozaki, Kouzo Hamada, Jun-Ichi Goto, Akinobu Suzuki, Etsuko Ebisui, Akiko Terauchi
-
Publication number: 20100167314Abstract: The present invention provides a composition comprising an IP3 receptor-binding protein (IRBIT), a nucleic acid that controls the expression and translation of IRBIT, or an antibody against IRBIT for controlling at least one intracellular biological function selected from the group consisting of (1) protein synthesis, (2) phosphatidylinositol metabolism, and (3) intracellular pH.Type: ApplicationFiled: March 20, 2007Publication date: July 1, 2010Inventors: Katsuhiko Mikoshiba, Hideaki Ando, Akihiro Mizutani
-
Patent number: 7709441Abstract: Analysis of substance capable of binding with inositol-1,4,5-triphosphate (IP3) receptor (IP3R), preferably with a regulation domain of IP3R; analysis of the function of IP3R; and establishing of a method of treatment or diagnosis for various malfunctions and diseases associated with IP3R. In particular, control of the activity of intracellular Ca2+ release. More specifically, a regulator for the activity of inositol-1,4,5-triphosphate (IP3) receptor (IP3R), comprised of carbonic anhydrase related protein (CARP); a control agent for intracellular calcium release, comprised of carbonic anhydrase related protein (CARP); and a method of control therewith.Type: GrantFiled: June 11, 2007Date of Patent: May 4, 2010Assignee: Japan Science and Technology AgencyInventors: Katsuhiko Mikoshiba, Junji Hirota, Hideaki Ando
-
Publication number: 20100087645Abstract: A bisboron compound represented by the general formula (I): wherein B represents a boron atom, Y represents an oxygen or sulfur atom, R1 and R2 independently represent a monocyclic aromatic group, a polycyclic aromatic group, or a heterocyclic group containing at least one heteroatom selected from oxygen, nitrogen and sulfur atoms, R3 represents a hydrogen atom; —(CH2)m—NR4R5; —CO—(CH2)m—NR4R5; —COCH(NH2)R6; —CHR7R8; —CH2CH(NH2)—R9; quinolyl substituted with C1-C4 alkyl group; or C1-C4 alkyl substituted with pyridyl, piperidino or pyrrolidinyl group, and X represents a monocyclic aromatic group, a polycyclic aromatic group or a heterocyclic group, which may be the same as or different from R1 and R2, or a bifunctional group having a monocyclic aromatic group, polycyclic aromatic group or heterocyclic group bonded to each side of a group selected from the group consisting of a single bond, O, CH2, S, SO2, CH2OCH2, OCH2, OCH2CH2OCH2, OCH2OCH2CH2 and CH2OCH2CH2, or a salt thereof, and a composition for contrType: ApplicationFiled: November 24, 2006Publication date: April 8, 2010Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Katsuhiko Mikoshiba, Shoichiro Ozaki, Akinobu Suzuki, Takeshi Nakamura
-
Publication number: 20100035360Abstract: This invention is intended to discover a novel autoantibody that can be used as a marker for an autoimmune disease and to provide an effective means for diagnosing an autoimmune disease. Disclosed is a reagent for detecting an autoantibody comprising an inositol 1,4,5-trisphosphate receptor (IP3R) protein and/or a fragment thereof.Type: ApplicationFiled: June 28, 2007Publication date: February 11, 2010Applicant: RikenInventor: Katsuhiko Mikoshiba
-
Publication number: 20080064082Abstract: Analysis of substance capable of binding with inositol-1,4,5-triphosphate (IP3) receptor (IP3R), preferably with a regulation domain of IP3R; analysis of the function of IP3R; and establishing of a method of treatment or diagnosis for various malfunctions and diseases associated with IP3R. In particular, control of the activity of intracellular Ca2+ release. More specifically, a regulator for the activity of inositol-1,4,5-triphosphate (IP3) receptor (IP3R), comprised of carbonic anhydrase related protein (CARP); a control agent for intracellular calcium release, comprised of carbonic anhydrase related protein (CARP); and a method of control therewith.Type: ApplicationFiled: June 11, 2007Publication date: March 13, 2008Applicant: Japan Science and Technology AgencyInventors: Katsuhiko Mikoshiba, Junji Hirota, Hideaki Ando
-
Patent number: 7276582Abstract: Analysis of substance capable of binding with inositol-1, 4,5-triphosphate (IP3) receptor (IP3R), preferably with a regulation domain of IP3R; analysis of the function of IP3R; and establishing of a method of treatment or diagnosis for various malfunctions and diseases associated with IP3R. In particular, control of the activity of intracellular Ca2+ release. More specifically, a regulator for the activity of inositol-1,4, 5-triphosphate (IP3) receptor (IP3R), comprised of carbonic anhydrase related protein (CARP); a control agent for intracellular calsium release, comprised of carbonic anhydrase related protein (CARP); and a method of control therewith.Type: GrantFiled: November 18, 2005Date of Patent: October 2, 2007Assignee: Japan Science and Technology AgencyInventors: Katsuhiko Mikoshiba, Junji Hirota, Hideaki Ando